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What Glaucoma Surgical Rate could Serve as a Target for 
West Africa? A Systematic Review
Egbula N Eni1, Winifred Nolan2, Bassey Eval3, John C Buchan4
Ab s t r Ac t 
Aim and objective: This study aimed to use the available evidence to model a glaucoma surgical rate (GSR), which could serve as a target for 
West Africa.
Materials and methods: A comprehensive literature search was performed in Medline, Embase, Global Health, and CINAHL, and studies published 
between January 1, 2000, and June 19, 2020, were retrieved. Study selection, quality appraisal, and data extraction were performed and the 
results of individual studies aggregated and presented using a narrative synthesis. Using these data, we aimed to construct a target GSR per 
million population per year that is sufficient to offer trabeculectomy to most patients with glaucoma who are diagnosed, and for whom other 
treatment options are either ineffective or inappropriate. The findings were then used to develop a trabeculectomy target for West Africa.
Results: Initial searches returned 633 references, of which 33 unique studies were eligible for inclusion. The glaucoma prevalence population-
based surveys identified, reported a wide range of prevalence of primary open-angle glaucoma (POAG) ranging from 1.0 to 8.4%. The studies on 
glaucoma medications reported intraocular pressure (IOP)-lowering effects ranging from 12.8% (beta-blockers) to 63.7% (Timolol–Latanoprost 
combinations). The adherence rate to antiglaucoma medications spanned from 10.3 to 82.3%. Regarding selective laser trabeculoplasty (SLT), 
only two studies were found. All the studies on trabeculectomy showed a significant reduction in IOPs at different follow-up periods with 
many reporting the absence of vision-threatening complications. From these available data, a GSR of 50 trabeculectomies was suggested for 
countries in West Africa.
Conclusion: This trabeculectomy target metric is expected to minimize POAG blindness in the West African subregion.
Clinical significance: The proposed GSR will enable eye care workers involved in glaucoma care in West Africa to assess their efforts compared 
with the proposed target. The gap will signal the potential for improvement.
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bAc kg r o u n d 
West Africa is believed to have the highest prevalence of primary 
open-angle glaucoma (POAG) in the world.1 Primary open-angle 
glaucoma accounted for 94.5% of glaucoma in a survey in Ghana,2 
and 86% of glaucoma in Nigeria.3 Despite this huge burden, 
the treatment of glaucoma in West Africa is fraught with several 
challenges including late presentation and diagnosis,4 poor 
compliance to medical therapy,5,6 reluctance of ophthalmologists 
to treat glaucoma with surgery,7 and refusal of glaucoma surgery 
by patients.8
The principal type of glaucoma surgery performed in West 
Africa is trabeculectomy.9 It is superior to medical therapy. Burr 
et al. in a Cochrane study in which they reviewed the results of 
four randomized controlled trials (involving 188 participants) 
which had compared trabeculectomy and medical therapy in 
adult POAG patients concluded that primary trabeculectomy 
was more successful in reducing intraocular pressure (IOP).10 
Trabeculectomy is, therefore, considering the current evidence 
base, arguably the most appropriate first-line treatment to 
address glaucoma blindness in West Africa at the population level. 
However, glaucoma blindness prevention can only be achieved if 
sufficient trabeculectomies are performed each year per million 
population; this is termed glaucoma surgical rate (GSR). This study 
aimed to identify, appraise, and synthesize existing evidence on 
glaucoma prevalence, treatment efficacy/complications, and 
adherence to glaucoma treatment in West Africa to use the data 
to model a target GSR for the region.
MAt e r i A l s A n d Me t h o d s 
Study Design
The study is a systematic review of population-based prevalence 
and incidence studies as well as glaucoma treatment and adherence 
studies in West Africa.
Ethical Considerations
Ethical approval was not required for this study since only secondary 
data which were fully in the public domain already were used. 
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Additionally, living people cannot be directly or indirectly identified 
by the data involved in this study.
Eligibility Criteria
Inclusion Criteria
• Studies on the population-based prevalence and incidence 
surveys of POAG.
• Glaucoma treatment efficacy and adherence studies.
• Studies on the outcomes of trabeculectomy and selective laser 
trabeculoplasty (SLT), including complication rates.
• Included studies must report new primary data.
• Included studies must be studies on West African subjects.
• Studies published from January 2000 to June 2020.
Exclusion Criteria
• Studies not conducted on humans.
• Letters and editorials.
Data Sources and Search Strategy
A comprehensive search of electronic databases Medline, Embase, 
Global Health, and CINAHL was undertaken. The search was 
conducted first in Medline with a subsequent translation of the 
search strategies into the other databases. This was complemented 
with hand-searching of reference lists and citation tracking of 
included studies in Google Scholar and other search engines. A 
combination of synonyms and subject headings (where available) 
for the following search concepts: “glaucoma”, “trabeculectomy”, 
“selective laser trabeculoplasty”, and “West Africa” was used to 
conduct the search. The search was put together using search 
tools like truncation, wildcards, proximity searching, and Boolean 
operators to combine the search concepts.
Given that West Africa comprises both English- and French-
speaking countries, language-specific filters were not employed 
in the search. This strategy was to guarantee retrieval of articles 
published in both French and English Language. The searches 
were, however, limited to studies conducted in West Africa and 
published between January 1, 2000, and June 19, 2020, because 
the study aimed to access a relatively new body of evidence that 
addresses the research questions considering that glaucoma care 
services are gradually evolving fields.
A variety of study designs was anticipated, so study-specific 
filters were not applied to the search. This approach was to ensure 
that a comprehensive search with greater sensitivity than specificity 
was run.
References retrieved from the searches were exported to 
Endnote X9 (Clarivate Analytics, Philadelphia, USA) management 
software and duplicate articles were removed. Articles identified 
underwent screening of their titles and abstracts to remove those 
that were clearly ineligible or irrelevant. The full text was retrieved 
for all potentially eligible studies. Two reviewers independently 
undertook the titles/abstracts as well as the full-text screening 
activity. Discrepancies between selected articles were settled 
through discussion between the reviewers and referred to an 
arbiter, where necessary.
Articles that could not be retrieved online were obtained 
directly from the authors through requests sent by emails. This 
approach ensured that the full text of all the articles that were 
needed was obtained.
A summary of the literature searching and sifting procedure is 
presented in Flowchart 1.
Risk of Bias and Quality Assessment
The quality of eligible studies was appraised with the Mixed 
Methods Appraisal Tool 2018 version (MMAT).11 MMAT was chosen 
because it is a valid tool that allows for quality assessment of 
quantitative, qualitative, and mixed methods study designs. 
It has been used in other systematic reviews.12 MMAT permits 
the evaluation of each study through the use of several criteria 
specific to the individual study design. The ratings of each criterion 
were used to judge the quality of the included studies. During 
Flowchart 1: Study selection process
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the development of this study protocol, it was anticipated that 
studies of different designs may be encountered given that studies 
featuring different interventions and measures of outcomes were 
needed to address the research questions. A single appraisal tool 
that comprises specific sets for different study designs was therefore 
preferred over other appraisal tools such as the Critical Appraisal 
Skills Programme (CASP). The methodological quality criteria for 
quantitative descriptive studies were used to assess the quality of 
the included studies as all the included studies turned out to be 
quantitative descriptive studies. All studies that met the inclusion 
criteria were included in the review regardless of their risk of 
bias.11 Therefore, even studies rated as “low quality” were included 
because such studies may still provide useful insight.13
Approach to Evidence Synthesis
Studies were categorized based on their outcome measures. Due to 
the considerable heterogeneity across the study designs and lack 
of consistent research questions, no opportunity for meta-analysis 
was found. The findings of each study within these groups were 
then summarized with frequencies and percentages for categorical 
variables. Quantitative variables, in contrast, were summarized 
using means and standard deviations for normally distributed 
data (such as IOP, a continuous variable) or median for skewed 
and/or data with outliers, such as age in some instances. Narrative 
synthesis involving the textual description of effects was then 
used to knit together the different findings including a summary of 
effect estimates, where available, based on the Synthesis Without 
Meta-analysis (SWiM) reporting guidelines.14 The entire results 
were aggregated and used to develop a GSR target that is needed 
to minimize glaucoma blindness in West Africa.
re s u lts 
A search of the databases was conducted on June 19, 2020. After 
de-duplication, 633 items were generated. A preliminary screening 
of titles and abstracts, where available, against the inclusion and 
exclusion criteria, was undertaken to leave behind 65 articles whose 
full texts were obtained and reviewed.
Seven population-based prevalence studies, one study on 
the incidence of glaucoma, 10 studies on efficacy and adherence 
to medical therapy of glaucoma, 2 SLT efficacy studies, and 13 
trabeculectomy outcome studies met the inclusion criteria. The 
remaining 32 out of 65 studies were excluded. Thus, overall, 33 
studies were included in the review. The search process and results, 
including the excluded studies and the reasons for their exclusion, 
are depicted in Flowchart 1. Five articles were in French,5,15–18 
and they were all translated to English. The remaining 28 were all 
published in English.
The included studies differ remarkably in samples, interventions, 
and measures of outcomes. The population-based glaucoma 
survey studies included participants aged 30 years and above; the 
glaucoma medication efficacy and adherence studies involved 
participants aged over 18 years; while two of the trabeculectomy 
studies19,20 included participants as young as 14 years. The 
methodological quality rating11 of included studies is set out in 
Tables 1 to 4.
Prevalence of Glaucoma from Population-based 
Glaucoma Surveys
Published population-based glaucoma surveys conducted in West 
Africa between January 2000 and 19 June 2020 are summarized in 
Table 1. Eight studies were found which measured this outcome. 
One of the studies21 measured the incidence of POAG in the Tema 
Eye Survey.2 It reported an 8-year cumulative incidence of 4.6% 
(95% CI: 3.5–6.0) which translated to an annual crude incidence of 
0.58 (95% CI: 0.4–0.8) and is not included in Table 1 which presents 
studies which all reported prevalence of glaucoma.
IOP-lowering Effects of Antiglaucoma Medications
Only 3 out of the 10 studies on glaucoma medications reported IOP 
lowering effects of antiglaucoma medications in POAG patients. The 
three studies were all conducted in eye facilities. Their findings are 
presented in Table 2.
Adherence to Antiglaucoma Medications
Six out of the 10 studies on glaucoma medications reported 
glaucoma medication adherence in POAG patients. The studies were 
all conducted in eye facilities. One study in the glaucoma medication 
category reported adherence to follow-up appointments in 
glaucoma patients diagnosed during a free eye screening in an eye 
facility. The findings of these seven studies are set out in Table 3.
IOP-lowering Effects of SLT
Only two studies that assessed the IOP-lowering effects of SLT were 
found. Both showed modest IOP-lowering effects.
IOP-lowering Effects of Trabeculectomy
Thirteen studies on the outcome of trabeculectomy for POAG 
were found. Twelve were retrospective patient record studies 
and one was a 1-year prospective longitudinal study which was 
conducted in a tertiary eye facility. The IOP-lowering effects of the 
trabeculectomies are shown in Table 4.
Table 1: Prevalence of glaucoma from population-based glaucoma surveys
First author (study score 
in parenthesis) Year Area
Prevalence of all glaucoma 
in percent (95% CI)
Prevalence of POAG 
in percent (95% CI) Age (years)
Sample 
size
Murdoch (2) 2001 Kaduna, Nigeria 1.02 (0.12–3.64) 1.02 (0.12–3.64) ≥45 196
Ekwerekwu (2) 2002 Enugu, Nigeria 2.1 – ≥30 664
Ntim-Amponsah (3) 2004 Akwapim-South, Ghana 8.9 8.40 (7.74–9.06) ≥30 1.843
Guzek (4) 2005 Volta region, Ghana 7.6 (6.5–8.5) – ≥40 2.298
Ashaye (4) 2013 Oyo, Nigeria 7.3 (5.5–9.1) 6.2 (4.5–7.8) ≥40 811
Budenz (5) 2013 Tema, Ghana 6.5 (5.8–7.1) 6.8 (6.2–7.4) ≥40 5.603
Kyari (5) 2015 Nigeria 5.02 (4.60–5.47) 1.53 ≥40 13.591
95% CI = 95% confidence interval
Key to study score: 2 = low, 3 = moderate, 4 = good, 5 = high
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Complications of Trabeculectomy
Twelve studies investigating complications of trabeculectomy as 
part of their outcomes in POAG patients were identified. These 
included a total of 1,288 eyes of POAG patients. Eleven were 
retrospective chart reviews, while one was a 1-year longitudinal 
study. Trabeculectomies were performed without adjunctive 
antimetabolites in three of the studies.22–24
Bekibele and Ashaye et al.24,25 reported shallow anterior 
chamber (14.2 and 17.1%, respectively) as the commonest early 
postoperative complication observed in their studies. The 
trabeculectomies reported by Bekibele were performed without 
adjunctive antimetabolites in 56 eyes of 34 patients aged 18–80 
years.24 Ashaye et al. assessed the postoperative complications 
in 25 eyes that had trabeculectomy with adjunctive 5-fluorouracil 
(5-FU) and 51 eyes without 5-FU.25
One retrospective patient record study that investigated the 
complications of trabeculectomy in 40 eyes without adjunctive 
antimetabolite and 6 randomly selected eyes with 5-FU augmented 
trabeculectomy reported hyphema as the commonest early 
postoperative complication observed (15.3%).26 Similarly, a 1-year 
longitudinal study of 5-FU augmented trabeculectomy in 45 POAG 
eyes reported hyphema as the most frequent complication (14.8%) 
in the early postoperative period.19
Most of the studies reported cataracts as a late complication 
with values ranging from 0.5%22 to 23.4%.20 Four studies20,22,27,28 
recorded endophthalmitis as complications with values ranging 
from 1.6%22 to 4.5%.27 Both Mielke and Ashaye and their 
respective colleagues25,29 through retrospective chart review 
compared the complication rates between eyes that had 5-FU 
augmented trabeculectomy and eyes without adjunctive 
antimetabolite. They concluded that the complication rates 
were similar in both groups. Likewise, two retrospective patient 
record studies28,30 compared primary trabeculectomy with 5-FU 
against primary trabeculectomy with mitomycin C and found 
that complications did not differ significantly between the two 
groups.
Estimation of Incidence
Mwanza et al.21 reported a crude annual incidence of POAG of 
0.58% in individuals aged 40 years and above in the Tema Eye 
Survey in Ghana. This is similar to the annual incidence that was 
obtained by Leske et al.31 in an African-descent aged 40–84 
years in Barbados. No other study which reported the incidence 
of glaucoma in West Africa was found, however, the Nigerian 
National Blindness and Visual Impairment Survey reported a 
glaucoma prevalence of 0.7 for all ages.32 Incidence can be 
estimated to be 10% of the prevalence. Hence, the incidence 
of glaucoma in Nigeria is about 0.07% for all ages or 0.50% in 
individuals aged 40 years and above,3 which is comparable to the 
incidence obtained in the Tema Eye survey.21
Table 2: Glaucoma medication efficacy studies
First author (study 
score in parenthesis) Year Area
Medications 
studied IOP-lowering effect Age (years) Sample size Research design
Sounouvou (3) 2012 Cotonou, Bénin Beta-blockers, 
Prostaglandin 
analogs








RE: 47.2 ± 21.6% LE: 48.8 ± 
15.8% RE: 12.9 ± 22.5% LE: 
19.6 ± 20.9% RE: 63.7 ± 1.6% 
LE: 61.4 ± 10.6%
30–100 141 Retrospective 
chart review
Gyasi (3) 2014 Accra, Ghana No restrictions Only 12.4% of IOP were con-
trolled to < 16 mm Hg at 12 
months from the initial mean 
IOP of 31.9 ± 8.9 mm Hg 
>18 163 Retrospective 
chart review
RE, right eye; LE, left eye
Key to study score: 3 = moderate
Table 3: Rate of adherence to antiglaucoma medications among primary open-angle glaucoma patients
First author (study 
score in parenthesis) Year Area Adherence rate Age (years) Sample size
Method of determining 
adherence
Omoti (3) 2005 Benin, Nigeria 33.9% 36–70 56 Self-reported
Tchabi (4) 2011 Cotonou, Bénin 53.3% 56.5 ± 11.9 
(median age)
120 Self-reported
Omolase (3) 2013 Ondo, Nigeria 66.0% 22–88 100 Self-reported
Onkoya (3) 2016 Lagos, Nigeria 82.33% ≥40 114 Self-reported
Santos (3) 2016 Lomé, Togo Good compliance (10.3%), fair 
(65.4%), poor (24.3%)
≥40 107 Self-reported
Kizor-Akaraiwe (2) 2019 Enugu, Nigeria 25.0% (adherence to follow-
up appointments)
50 (median age) 116 Self-reported through 
telephone interview
Saka (2) 2020 Sagamu, Nigeria 81.6% ≥65 60 Retrospective chart 
review
Key to study score: 2 = low, 3 = moderate, 4 = good
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GSR Target for West Africa
The ideal GSR for West Africa was derived as shown in Flowchart 2 
using available evidence from Nigeria as only this country reported 
the required data needed for such modeling. The Nigeria National 
Blindness and Visual Impairment Survey reported the prevalence of 
glaucoma for all ages32 from which a glaucoma incidence of 0.07% 
as stated above was derived.
A GSR could be proposed that was equal to incidence, or even 
higher than the incidence to tackle the backlog of unoperated 
cases. However, such a target would be an overestimate as many 
cases remain undiagnosed and some patients will decline surgery 
or be managed by other means. Using these data, we aimed to 
construct a target GSR per million population per year that is 
sufficient to offer trabeculectomy to most patients with glaucoma 
Table 4: Trabeculectomy studies—intraocular pressure (IOP)-lowering effects
First author 
(study score in 
parenthesis) Year Area Antimetabolite IOP-lowering effectsa Age (years) Sample size Research design
Agbeja-Baiyero-
ju (3)
2001 Ibadan, Nigeria None IOP ≤ 21 mm Hg in 92% 48.1 (mean age) 264 POAG eyes Retrospective 
chart review
Anand (3) 2001 Lagos, Nigeria None IOP < 22 mm Hg = 71% 
at 5 years, IOP < 16 mm 
Hg = 46% at 5 years




Bekibele (3) 2001 Ago-Iwoye, 
Nigeria
None IOP < 21 mm Hg = 
74.1% at 2 months
18–80 (54 years 
mean age)




Mielke (3) 2003 Lagos, Nigeria 5-FU in 76 eyes, 
No 5-FU 78 eyes 
(controls)
IOP ≤ 14 mm Hg = 64% 
(5-FU group) and 39% 









Gyasi (3) 2006 Bawku, Ghana None IOP < 18 mm Hg = 
67.95% at 6 months.
17–85, 50.6 
(mean age)






2007 Osun, Nigeria 5-FU in only 6 
eyes
IOP ≤ 20 mm Hg in 
73.3% at 1 year in the 
5-FU group, 61.8% in 
the rest
43.5 ± 3.5 
(mean age)
46 eyes of 35 
POAG patients
Lawan (2) 2007 Kano, Nigeria 5-FU IOP of 10-15 mm Hg 
was 82% at 6 months to 
5 years




Kim (3) 2008 Cape Coast, 
Ghana
5-FU in 38 eyes, 
MMC in 30 eyes
IOP < 21 mm Hg in 
24.3% of eyes in the 
5-FU group and 55.2% 
of eyes in the MMC 
group
65.9 (mean age 
for 5-FU group), 
64.7 (mean age 
for MMC group)




Ashaye (3) 2009 Ibadan, Nigeria 5-FU in 25 eyes Mean IOP of 17.8 
mm Hg at one year from 








Komolafe (3) 2011 Ibadan, Nigeria 5-FU Mean IOP of 16.9 
mm Hg at 72 weeks 
from a preoperative 
mean of 27.7 mm Hg
49.8 ± 9.33 
(mean age)




Anand (3) 2012 Lagos, Nigeria 5-FU in 73 eyes, 
MMC in 59 eyes
IOP < 15 mm Hg at 3 
years was 55% (95% 
CI: 44–70%) in 5-FU 
eyes and 76% (95% CI: 
66–89%) in the MMC 
group
60.5 ± 11.8 and 
57.4 ± 12.4 
(mean ages) 




Olawoye (4) 2013 Ibadan, Nigeria 5-FU Mean IOP at 1 year was 
12.3 mm Hg from a 
preoperative mean of 
31.9 mm Hg
14–77, 48.9 ± 
19.6 (mean age)




Olawoye (3) 2017 Ibadan, Nigeria 5-FU Mean IOP of 15.4 
mm Hg at 43 months 
from a preoperative 
mean of 31.9 mm Hg
14–77, (52 years 
median age)




aIOP with no additional antiglaucoma medication; 5-FU, 5-fluorouracil; MMC, mitomycin C
Key to study score: 2 = low, 3 = moderate, 4 = good
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who are diagnosed, and for whom other treatment options are 
either ineffective or inappropriate.
Flowchart 2 presents a flowchart of effectiveness based on the 
reviewed evidence. It is a best-case scenario, hence, was developed 
from best effectiveness studies that were identified in this review. 
Two studies33,34 were able to achieve 80% adherence which is the 
minimum regarded as good adherence to medications,35 so this 
proportion of medication adherence was assumed in the best-case 
scenario model (Flowchart 2). Only 25% of patients are expected 
to have adequate control of IOP (mean IOP ≤ 18 mm Hg) on drops 
at 6 months,36 and for our model, we, therefore, assigned 75% of 
diagnosed glaucoma cases as requiring trabeculectomy. The 75% 
cut-off also ensured that an achievable target is developed,37 in 
addition to the fact that in practice not all POAG patients will be 
fit for surgery.
In a previous study, only 1.4% of patients offered trabeculectomy 
actually attended the surgery.4 The best IOP-lowering effects from 
trabeculectomy in the present study using the findings of Advanced 
Glaucoma Intervention Study (AGIS) as stated above as benchmark 
for good IOP control was achieved in 82% of eyes at 6 months to 5 
years.38 The 18% of eyes with failed trabeculectomies may therefore 
require a redo trabeculectomy or glaucoma drainage device surgery 
where the latter is available (Flowchart 2).
Based on the incidence and treatment effectiveness data, 
the ideal minimum number of trabeculectomies that need to 
be performed each year in a district of one million population in 
West Africa to have any impact on the backlog of POAG patients 
yet to benefit from the surgery is 50 (Flowchart 2). The available 
current evidence suggests the highest number of trabeculectomies 
performed annually in a health district of one million population 
in West Africa is about 4 (Flowchart 2) leaving a gap of 46 which 
need to be addressed.
di s c u s s i o n 
Minimizing blindness from glaucoma starts with planning for 
glaucoma service provision. The planning will be more effective 
if there is a target GSR. The prevalence and incidence of POAG as 
well as the outcomes of the different treatment modalities for this 
eye disease determine the GSR.
Considering that POAG constitutes the major type of glaucoma 
in West Africa and that some centers sometimes treat the other 
relatively rare types of glaucoma with trabeculectomy,25 it appears 
plausible that estimating a GSR based on the prevalence of 
glaucoma for all ages will be more practical in the subregion. This 
will also reduce the underestimation that could result by not taking 
into consideration that a significant number of individuals aged <40 
years also benefit from trabeculectomy, due to the relatively early 
onset of the disease in West Africa. For example, in Ghana, Ntim-
Amponsah and colleagues39 reported an age-specific prevalence of 
POAG of 6.0% in people aged 30–34 years, and 6.7% in individuals 
aged 35–39 years.
The IOP-lowering effects of antiglaucoma medications on POAG 
patients ranged from 12.8% with the use of beta-blockers17 to 63.7% 
with the use of Timolol–Latanoprost combination40 (Table 2). This 
evidence is, however, weak because all the three studies17,36,40 that 
reported the IOP-lowering effects of medical treatment of glaucoma 
were retrospective patient record studies which are prone to 
selection and misclassification bias.
The six studies that reported glaucoma medication adherence 
in POAG patients presented a wide range of values that stretched 
Flowchart 2: Glaucoma surgical rate target
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from 10.3%5 to 82.3%33 (Table 3). While many studies reported 
compliance levels that were so low that it will be reasonable to 
conclude that medical therapy for glaucoma was inappropriate 
in this population, two studies achieved an acceptable 80% 
adherence35 so we are working with this as an acceptable best-
case scenario. Glaucoma patients who are found to exhibit poor 
adherence to their antiglaucoma medications could be good 
candidates for trabeculectomy. A key advantage of trabeculectomy 
over the medical treatment of glaucoma is the elimination of the 
adherence factor. From a cost perspective, trabeculectomy also has 
an edge over the medical treatment of glaucoma as it is cheaper 
in the long run given that it is often a one-off procedure for many 
patients.41 This has led to the suggestion that glaucoma surgery 
could be a better approach to addressing the burden of glaucoma 
in developing countries.42
Only two studies18,43 that examined SLT were found in this 
review. Although both studies reported a modest reduction in 
IOP, they are inadequate to allow plausible conclusions to be 
drawn, especially regarding its widespread use in West Africa. The 
paucity of studies on SLT in the sub-region might suggest that the 
procedure is not yet widely practiced. However, the procedure could 
be a useful treatment modality (where it is available) that may avoid 
some glaucoma patients from undergoing surgery.
The available evidence from this review suggests that among 
West African populations, trabeculectomy lowers IOP to an average 
level in the low19,30,38 to mid-teens,20,23,25,27,29 especially when 
augmented with either intraoperative mitomycin C or 5-FU both 
of which potentiate its IOP-lowering effect19,20,26,28–30 (Table 4). 
This is particularly important because many glaucoma patients 
in the sub-region often present late in an advanced stage of the 
disease,4 with the need for their IOPs to be controlled in the low 
to mid-teens. The AGIS showed that IOPs consistently <18 mm Hg 
following trabeculectomy in POAG patients aged between 35 and 
80 years with failed medical therapy is associated with only minor 
deterioration of the visual field over 6 years.44
Studies that investigated the complications of trabeculectomy 
reported various types of complications. A few of the complications 
were vision-threatening. These included cataracts with a 
complication rate that ranged from 0.5%22 to 23.4%,20 and 
endophthalmitis, 1.6%22 to 4.5%.27 Since trabeculectomy like every 
other surgery has its own complications, a threshold for surgery 
will be justified based on the complication rates found in these 
studies. Such threshold for trabeculectomy will also depend on the 
life expectancy at birth, which for instance, is 61.49 years for Ghana 
and 53.05 years for Nigeria.45
The incidence of open-angle glaucoma increases with age,31 
but the life expectancy at birth of West African populations is 
relatively low.45 These factors combined, create a pyramid of disease 
for POAG, where they are more people with early glaucoma (some 
of whom will die with the condition before it causes too much 
reduction in quality of life) than those with advanced disease. This 
creates a tipping point–if POAG patients are operated on at the very 
first sign of nerve damage that looks glaucomatous–there may be 
unnecessary complications that could have been avoided if the 
ophthalmic surgeon had waited as some of those people may die 
before the disease progresses too far.
In one of the reviewed studies,20 almost one in every four POAG 
who had trabeculectomy developed visually significant cataracts 
after at least 2 years of follow-up. Thus, to prevent this complication 
and other complications associated with trabeculectomy, at least 
a quarter of POAG patients that could be managed successfully 
with medical therapy and/or SLT, where the latter is available, can 
be spared trabeculectomy. Deducing from this, the remaining 75% 
may benefit from trabeculectomy with minimal complications. 
Additionally, using the findings of AGIS44 as a benchmark for 
successful IOP control, the best reported IOP control in this review 
(mean IOP consistently ≤18 mm Hg) for patients on topical glaucoma 
medications at 6 months was achieved in 25% of patients.36 Based 
on these findings, a practical GSR is best computed from 75% of the 
population of POAG patients. This would be a GSR targeted at POAG 
patients with clearly progressive disease who are very likely to go 
blind without trabeculectomy. These assumptions were utilized in 
the calculation of the GSR.
The minimum number of trabeculectomies that need to be 
performed each year in West Africa, based on the available evidence 
is 50 in a health district with one million population. This should 
be the minimum target set by eye care workers involved in the 
management of POAG patients in the sub-region. Analogizing from 
the control of cataract blindness,46 this is the minimal GSR that 
would reduce the trabeculectomy backlog and very likely reduce 
the rate of blindness from POAG in the sub-region.
A GSR of 7.0 and 2.9 was estimated for Ghana and Ivory Coast, 
respectively, in a previous study that was designed to estimate the 
global rates of glaucoma surgery.9 A GSR of 7 is about 7 times lower 
than the minimum target of 50 proposed in this study. Similarly, a 
GSR of 2.9 is 17 times less than the trabeculectomy surgical rate 
of 50 modeled in this study. This suggests that the current GSR in 
West Africa is still abysmally low, especially when compared to rates 
obtained in the European region which ranged from 500 in Germany 
to 85.2 in the Netherlands.9 These European studies considered 
a wide variety of glaucoma surgeries including trabeculectomy 
(77.7% of the entire glaucoma surgeries), glaucoma drainage device 
implantation, and cyclodestructive procedures, among others. 
However, 100% of the glaucoma surgery reported by Ivory Coast’s 
National Prevention of Blindness Committee was trabeculectomy.9
The present study has estimated a GSR that could serve as 
a glaucoma surgery (trabeculectomy) target for West Africa. 
Analogous to cataract surgical rate (CSR) the metric GSR will allow 
easy comparison between West African countries and serve as a 
yardstick on which adequacy of surgical care of glaucoma patients 
in the region can be measured. The gap between the aspirational 
number of 50 trabeculectomies per million population per year 
and the actual number of trabeculectomies performed presently 
which is an average of 4 (an optimistic estimate of current GSR) 
(Flowchart 2) will signal the potential for improvement by 
ophthalmologists caring for POAG patients in West Africa.
li M i tAt i o n s 
The current study is the first to present a target GSR (with 
trabeculectomy as the specific surgery) for West Africa taking into 
consideration medical treatment of glaucoma and the use of SLT 
as other viable treatment options. Consequently, it is likely to be 
fraught with assumptions and limitations. First, most of the studies 
reviewed are observational studies that are prone to bias. Second, 
no relevant unpublished studies could be assessed for inclusion 
in this study. There is therefore the possibility of publication bias.
Finally, most of the studies included in this review used 
insufficient standardization in reporting outcomes of the treatment 
of glaucoma. This hampered synthesis of findings across studies. 
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This particular limitation can be surmounted by using a standard 
outcome framework in research studies, such as proposed by the 
International Consortium for Health Outcomes Measurement 
(ICHOM).47
These limitations notwithstanding, this review provides a 
useful trabeculectomy target for West Africa. It highlights the need 
for eye care centers involved in glaucoma care in West Africa to 
start undertaking a routine audit of the numbers, outcomes, and 
complications of trabeculectomy in their centers. Such data could 
then be pooled nationally so that each West African country can 
assess how they stand compared to this proposed target.
co n c lu s i o n 
Available evidence suggests that the prevalence of POAG is probably 
highest in West Africa. Most studies in West Africa rank glaucoma 
second to cataract as the commonest cause of blindness. This review 
found that medical treatment of POAG is inadequate to achieve the 
desired target IOP in most patients. This finding may be related to 
the poor adherence to antiglaucoma medications reported by most 
studies in the sub-region. Trabeculectomy, on the other hand, was 
found to be an effective surgical procedure for managing POAG 
in West Africa. With this in mind, a conservative estimate of the 
number of trabeculectomies needed to be performed in a year in 
a health district of one million population (GSR) in West Africa is a 
minimum of 50. This target metric is expected to minimize POAG 
blindness in the West African sub-region.
Available evidence suggests that SLT is not yet widely available 
as a treatment modality for POAG in West Africa. It is, however, a 
viable treatment option that could save some POAG patients from 
surgery, in centers where it is available.
cl i n i c A l si g n i f i c A n c e 
The GSR target will provide eye care workers, program managers, 
and policymakers with a tool that will guide clinical and policy 
decision-making regarding the care of glaucoma patients in the 
region. It will provide a target for eye care providers to work toward 
while developing glaucoma services in West Africa.
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